

Date: 15th May, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Investor Presentation on Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2026

Please find enclosed herewith the Investor Presentation on the Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2026.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED



Alembic Pharmaceuticals Limited

Investor Presentation Q4 FY26

Safe Harbour Statement




The materials and information presented herein may include forward looking statements , which reflect current expectations, projections, and assumptions. These statements are inherently subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those anticipated.

Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product related, forward-looking statements. Product risks and uncertainties include but are not limited to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost containment, and governmental laws and regulations affecting domestic and foreign operations.

Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to the inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.

Quarterly Snapshot



Key Highlights

Revenue

India Branded Business

Achieved a 4% YoY growth with quarterly revenues of INR 5.68 billion.

US Formulation

The business recorded a 11% year-over-year increase, driven by key product launches and gains in market share across select therapies.

Ex-US Formulation

The quarter recorded De-Growth of -2% year-over-year, while continued focus remains on expanding offerings and strengthening market reach.

API

The business reported consistent growth of 2% in Q4.

Profitability

Pre R&D EBITDA

Pre R&D EBITDA margin increased from 24% to 25%; 8% year-over-year growth.

R&D Spend

R&D expenses increased by 39%, driven by one-off peptide development and higher filings compared to the previous year.


Revenue Summary



INR Bn

Business	Q4 FY25	Q4 FY26	Y-o-Y
Formulations			
India Branded Business	5.45	5.68	4%
US	5.08	5.64	11%
Ex-US	3.75	3.69	-2%
API	3.42	3.47	2%
Total Revenue	17.70	18.48	4%

FY25	FY26	Y-o-Y
23.39	24.58	5%
19.57	22.06	13%
12.43	14.94	20%
11.33	11.87	5%
66.72	73.45	10%




India Branded Business – Performance



Revenue Q4 FY26

Growth: 4%


INR Bn




Revenue Trend

CAGR: 6%

INR Bn



Sales Mix Q4 FY26



- > The India Branded Business recorded 4% growth with revenues of INR 5.67 billion for the quarter.
- > Alembic is ranked 21st in the Indian Pharmaceutical Market (IPM).
- > 13% of the product portfolio is listed under NLEM.
- > Sales operations include 5,500+ Medical Representatives across 21 marketing divisions.
- > Holds a 1.2% market share of the Indian pharma space.*
- > Four flagship brands have surpassed INR 1 billion in sales.*

India Branded Business – Rx Driven Rankings




Top Brands with Rank and Market Share

BRANDS	Rank Q4 FY 26*	MS% Q4 FY 26*	BRANDS	Rank Q4 FY 26*	MS% Q4 FY 26*
AZITHRAL	1	30.1	FREEGO	2	8.5
CRINA-NCR	1	29.4	WIKORYL	3	10.1
ALTHROCIN	1	84.2	BROZEET-LS	3	6.3
ROXID	1	94.0	ISOFIT	3	5.7
DELTONE	1	51.6	ULGEL	3	7.6
GERIJOINT	1	30.4	BLADMIR	3	8.8
ELATA	1	54.1	CLOFF	4	11.3
CETANIL	2	6.7	ETRIK	4	5.0
GESTOFIT SR	2	18.1	VELDROP	4	4.3
LACTONIC	2	22.1	BILAMBIC-M	4	5.7
ESTROPLUS	2	34.8	OVIGYN DH	4	11.0
ISOFIT SR	2	14.5	TELLZY	5	3.5
TRAVISIGHT	2	19.9	SHARKOFERROL	5	6.0
UNIGOLIX	2	13.7	HARMONI	5	4.5




* Above market growth is based on the respective molecule group.

Driving Overall Prescription Business



> Alembic ranks 17th by prescription volume, with a total of 136.5 million prescriptions (MAT Mar 2026).

Animal Health Business




- > Alembic operates in the Livestock, Poultry, and Companion Animal segments.
- > Market leader in Haematinics and Antibiotics with brands such as Sharkoferrol, Moxel, Xceft and Mceft.
- > Established portfolio of strong brands continues to drive growth.

Annual Sales Value	INR Mn			
	Above 300	200 - 300	100 - 200	20 - 100
No. of Brands	6	1	6	19

Revenue Q4 FY26

Growth: 11%


INR Bn




Revenue Trend

CAGR: 7%

INR Bn



Approved ANDAs



■ Oral Solids ■ Derma ■ Ophthalmic ■ Injectable ■ Inhalation

Total 235*

* Includes 19 Tentative Approvals

Q4FY26 : 5 ANDA Filings, 4 Approvals.

Cumulative : 274 ANDA Filings, 235 approvals and 178 Products Launched so far.

- > Established US front-end with a strong customer base.
- > 15 products launched in FY26 with a total number of 178 products commercialized as on date.
- > Focused on strategically evolving the portfolio and pipeline across complex platforms and specialty segments.
- > US Branded business: Launched in Q4 positioning us to expand our footprint in branded drugs in the US.


Ex-US Business



Revenue Q4 FY26

De-Growth: -2%

INR Bn




- > Key partnerships active in Europe, Canada, Australia, Brazil, Chile and South Africa.
- > Quarterly performance for the Ex-US Market was muted due to higher base effect and one-off variances.
- > Future growth to be supported by product launches and geographical diversification. Subsidiary set up in Thailand, Philippines & Germany.

Revenue Trend

CAGR: 18%

INR Bn




API Business



Revenue Q4 FY26

Growth: 2%


INR Bn



Revenue Trend


CAGR: 6%

INR Bn



- > Recorded 2% YoY growth, led by strong volumes and tempered by pricing challenges.
- > 6 US DMF filed in Q4 FY26. 149 Cumulative DMF filings with the US FDA.
- > Continued focus on cost efficiency to remain competitive.


Dosage Form-wise ANDA Approval and Launch – Q4 FY26




R&D Capabilities

Formulation & API: Vadodara and Hyderabad Bio Centre : Vadodara

Continued investment in building product pipelines




Rising ANDA filings and approvals



Change in total approvals (Final + Tentative) during the FY

R&D Spend Q4-FY'26



Q4 Financials Summary – Profit & Loss statement









INR Bn

Particulars	Q-4 FY25	Q-3 FY26	Q-4 FY26	YoY(%)	QoQ(%)	FY 25	FY 26	YoY(%)
Revenue from Operations	17.70	18.76	18.48	4%	-2%	66.72	73.45	10%
Other Income	0.14	0.15	0.26			0.43	0.54	28%
Total Income	17.84	18.92	18.73	5%	-1%	67.15	73.99	10%
Material Consumption	5.31	5.29	5.32	0%	1%	17.93	19.84	11%
Employee benefits expense	3.94	4.33	4.39	12%	1%	15.62	17.32	11%
Finance Costs	0.25	0.23	0.23	-8%	-3%	0.79	0.94	19%
Depreciation & Amortization Expense	0.69	0.80	0.89	28%	11%	2.79	3.19	14%
Other Expenses	5.74	6.21	6.49	13%	4%	23.08	25.10	9%
Total Expenses	15.91	16.86	17.31	9%	3%	60.21	66.39	10%
Profit before Share of Profit / (Loss) of Associates	1.93	2.06	1.42	-26%	-31%	6.93	7.61	10%
Share of Profit / (Loss) of Associates & Joint Ventures	-0.01	-0.02	0.01			0.01	0.00	
Profit Before Exceptional	1.92	2.04	1.43	-25%	-30%	6.94	7.61	10%
Exceptional Item	0.00	-0.42	-0.25			0.13	-0.67	
Profit Before Tax	1.92	1.61	1.19	-38%	-27%	7.07	6.94	-2%
Tax Expense (Credit)	0.35	0.30	-0.83			1.25	0.23	
Profit for the Period	1.57	1.32	2.02	29%	53%	5.82	6.71	15%
Non-controlling interests	0.00	0.01	0.01			0.01	0.04	
Profit for the Period attributable to shareholders	1.57	1.33	2.03	29%	52%	5.83	6.75	16%
Gross Margin	70%	72%	71%			73%	73%	
EBIDTA Margin before Exceptional	16%	16%	14%			16%	16%	
PBT Margin before Exceptional	11%	11%	8%			10%	10%	
PBT Margin	11%	9%	6%			11%	9%	
PAT Margin	9%	7%	11%			9%	9%	
R&D Expenses as % Revenue	9%	9%	11%			8%	10%	

Yearly Financials



INR Bn



Note : FY23 numbers are without considering one-time impact of Aleor write off for better comparison

* Excluding Assets not deployed & Exceptional Items.

> Alembic's ESG Targets

Net Zero by 2050

- 63% GHG Emission reduction by 2034
- 90% GHG Emission reduction by 2050 (Approved by SBTi)

Water Neutrality by 2027

50,000 trees by 2027

Environment



Social



Governance



- We are one of the 10 Indian Pharma companies with approved targets under SBTi
- Commissioned 24 MW solar park at Bhatpur, Vadodara
- 20% Reduction in specific water consumption (KL/MT)
- 81% treated water recycled
- Developed 112 recharge wells
- Planted 25,000+ trees
- 16% Reduction in landfill waste
- Improved ratings in carbon disclosure project

- Zero fatality
- Great place to work certification for 3rd consecutive year
- 7% increase in safety observations
- 2,44,460 beneficiaries impacted through CSR Initiatives

- Implemented supplier Code of Conduct and the sustainable procurement policy
- 27% critical vendors assessed against the ESG criteria
- Initiated a comprehensive organizational risk assessment

Company Overview

Company at a Glance



Mission

Improve Healthcare with innovation, commitment and Trust



Team Size

17,200+



ANDA Filings

274 (Mar 31,2026)



R&D Centers

2



Manufacturing Facilities

10



Prescribers in India

2,46,000



Field Force

5,500+



Brands

208



Net Zero Target

2050



Generics Formulation in the USA

178

Value Proposition



Developing a specialty drug pipeline for India



Exploring opportunities in Injectables

21

Ranks 21th in the Indian formulations market



Consistent dividend payout



Supplying APIs to 60+ countries globally



Established presence in Chile & UAE




Expanding product portfolio in the USA



Strengthening presence in Canada, South Africa, LATAM & Middle East

The Journey



Robust Infrastructure



Location	Dosage Form	Last USFDA Audit
International Generics		
F1 - Panelav	General Oral Solids	July'24
F2 - Panelav	Oncology Oral Solids	Mar'24
	Oncology Injectables	Oct'24
F3 - Karkhadi	General Injectables & Ophthalmic	Feb'26*
F4 - Jarod	General Oral Solids	Nov'24
F5 - Karkhadi	Various derma forms	Mar'23
API		
API I & II – Panelav		May'25
API III - Karkhadi		Mar'25

* F3 : Response of observations (FDA Form 483) is submitted. EIR is awaited.

Location	Dosage Form	Last WHO Audit
India Formulation-Indore	Oral Solids & Liquid	Mar'26*

* Certification received in Apr'26.



F2 - Panelav



F3 - Karkhadi



F4 - Jarod



F5 - Karkhadi



Thank You

For further queries, please contact:

Mr. Ajay Desai

ajay.desai@alembic.co.in

022-6695 3681

Investor Relations Advisors

Adfactors PR Pvt. Ltd.

Snighter Albuquerque

snighter.a@adfactorspr.com

Darshan Mankad

darshan.mankad@adfactorspr.com

2nd Floor, Prime Corporate Park

Sahar Road, Andheri East

Mumbai 400 099

www.alembicpharmaceuticals.com